{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-269415","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.673960+00:00","generated_at":"2026-06-09T00:20:39.049757+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Director Scott Myers resigns from Viridian board; company adopts amended bylaws effective Nov 1, 2023","bullets":["Scott Myers resigned from the board effective Oct 29, 2023; departure not due to any disagreement with the company.","Board adopted Third Amended and Restated Bylaws effective Nov 1, 2023.","Bylaws modify notice period required to call a special meeting of the Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-269415","json":"https://secwatch.observer/filing/0001193125-23-269415.json","markdown":"https://secwatch.observer/filing/0001193125-23-269415.md","text":"https://secwatch.observer/filing/0001193125-23-269415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/0001193125-23-269415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/d557083d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:20:39.049757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61728244ea","claim":"Scott Myers resigned as director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On October 29, 2023, Scott Myers resigned as a member of the board of directors (the \"Board\") of Viridian Therapeutics, Inc. (the \"Company\"), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/0001193125-23-269415-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"c50e7e8f7eb1a1abef44b919e81660ac74afd69b","claim":"Viridian Therapeutics, Inc.\\DE: The Board adopted the Third Amended and Restated Bylaws, modifying the notice period required to call a special meeting of the Board (effective 2023-11-01).","evidence_excerpt":"Effective November 1, 2023, the Board adopted the Third Amended and Restated Bylaws of the Company (the “Bylaws”). The Bylaws, among other things, modify the notice period required to call a special meeting of the Board.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/0001193125-23-269415-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-11-01"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}